Akademik Veri Yönetim Sistemi
4th International Eurasian Conference on Science, Engineering and Technology (EurasianSciEnTech 2022), Ankara, Türkiye, 14 - 16 Aralık 2022, ss.28, (Özet Bildiri)
Metformin is an oral biguanide used for the treatment of type 2 diabetes mellitus (T2DM). Metformin has been shown to have
anti-cancer effects in various hormone-sensitive tumors, such as breast cancer, pancreatic cancer, colon cancer, and prostate
cancer. The aim of the present study was to evaluate the possible protective effects of metformin on small intestine damage
in Dunning prostate cancer model. In this study, male Copenhagen rats were divided into six groups: Control group: 0.9%
physiological saline was given for 14 days; Diabetic group: only injected single dose of streptozotocin (STZ) (65mg/kg);
Cancer group: 2x104 Mat-LyLucells were inoculated subcutaneously; Diabetic + cancer (DC) group: inoculated with 2 x 104
MAT-LyLu cells and STZ injection; Cancer+metformin group: metformin (250 mg/kg) was administered during the
experimental period, following inoculation of Mat-LyLu cells; Diabetic + cancer + metformin (DCM) group: metformin
administered for 14 days together with STZ and Mat-LyLu cells. At the end of the study, all the animals were sacrificed and
small intestine tissues were taken. Intestinal samples were homogenized in physiological saline for biochemical studies and
fixed in Bouin solution for histological examinations. Total antioxidant (TAS), total oxidant (TOS), reactive oxygen species
(ROS), interleukin-1β (IL-1β), interleukin-6 (IL-6) and sialic acid (SA) levels and acetylcholinesterase (AChE), sucrase and
maltase activities were estimated in small intestine homogenates. According to the results, TOS, ROS, IL-1β, IL-6 and SA
levels and sucrase and maltase activities were found to increase, while TAS level and AChE activities were decreased in the
diabetic, cancer and DC groups as compared to control group. Administration of metformin reversed these effects.
Histological evaluation showed moderate to severe damage to the small intestine following the diabetes and cancer process.
The findings of this study reveal that histopathological damage in cancer and diabetic+cancer groups decreased significantly
in the metformin treated groups. In this study, it was observed that metformin prevented the damaged caused by MAT-Lylu
metastatic cells in rats small intestine.